◆ 会议时间：2026年3月16-18日
◆ 会议地点：法国 巴黎
◆ 会议简介：
2026年ESMO国际靶向抗癌治疗大会(TAT2026)将于2026年3月16-18日在法国巴黎举行，会议由欧洲肿瘤内科学会(ESMO)组织。靶向抗癌治疗(TAT)大会是ESMO官方年度会议，自2018年开始每年在欧洲举办。TAT会议是专注于讨论早期药物开发和转化研究的首要论坛，会议议题涵盖靶向药物、免疫肿瘤学和涉及此类药物的组合等方面。来自学术界和工业界的领导者、临床医生、研究人员和监管机构一起共同努力，加快开发新的抗癌治疗方法以提高患者的预后效果。
欧洲肿瘤内科学会（ESMO）成立于1975年，是全球领先的肿瘤内科学专业组织。ESMO是肿瘤学教育和信息的参考学会，现在全球160多个国家和地区拥有超过25,000余名会员；ESMO致力于通过宣促进多学科的癌症护理，支持肿瘤学家的专业发展以及在全球倡导可持续的癌症护理，尽而为癌症患者提供最佳的护理。未经许可禁止复制摘录转载本站任何内容-国际医学会议网（lingyuint.com）.
ESMO TARGETED ANTICANCER THERAPIES CONGRESS 2026
Date:
16 -18 March 2026
Location:
Palais des Congrès de Paris, Paris, France
Plan your participation in the ESMO Targeted Anticancer Therapies Congress 2026, taking place from 16 to 18 March 2026 in Paris, France.
The journey of innovation in cancer treatment begins with early drug development. ESMO TAT serves as a dynamic, multi-stakeholder forum, uniting researchers, industry leaders, investors, regulators, and patient advocates under one roof to accelerate the delivery of life-changing anticancer therapies to patients.
Join us in the pursuit to advance cancer treatment: we look forward to seeing you at this transformative event, to share new data, foster collaboration, and tackle challenges that will drive early clinical development forward.
Innovate. Collaborate. Advance.
ESMO TAT 2026 Scientific Co-Chairs
Elena Garralda
Barcelona, Spain
Carlos Gomez-Roca
Toulouse, France
Cristian Massacesi
New York, USA
摘要征文投稿：
Abstract submission deadline
Tuesday, 16 December 2025, 21:00 CET (Central European Time)
点此提交摘要>>>Submit Abstract>>>
Abstract submission categories
- Antibody-based therapies
- Artificial intelligence (AI) and digital therapeutics
- Cellular and gene therapies
- DNA damage repair and epigenetics
- Immunotherapy
- Kinase-targeting agents and cell signalling modulators
- Methodological, financial and regulatory aspects
- Molecular profiling applications
- Miscellaneous
Outcome notifications
Outcome notifications are expected to be made available to first authors by end-January 2026.
Abstract presenter registration
Registration is mandatory for all accepted presentation formats, including ePoster. The presenting author or the designated replacement presenter must be registered (ie. registration fees paid) by 25 February 2026. Should the Presenter (or designated replacement presenter) not be registered by the given deadline, the abstract will be excluded from presentation in the ESMO TAT 2026 programme, and removed from the online programme and publication in the ESMO TAT 2026 Abstract Book.
Presentation and publication of accepted abstracts
The ESMO TAT 2026 Scientific Committee will select abstracts for presentation during the Congress and determine the format of the presentations based on the following possibilities:
- Proffered Paper – Oral presentation of original data of superior quality, followed by expert discussion and perspectives.
- Mini Oral – Short oral presentation of good quality data, followed by expert discussion and perspectives.
- Poster – Paper poster presentation for review and discussion onsite. Presenting authors must attend the Congress in person to represent their work. Preparation of an ePoster is also mandatory for inclusion in the Congress Virtual Platform and onsite digital screens.
- ePoster – Electronic poster (ePoster) in PDF format for display onsite on digital screens. Presenting authors of ePosters are not required to attend the Congress in person to represent their work. Paper posters are not to be prepared, and poster boards will not be provided.
Accepted abstracts will be published post-Congress, online only, in the ESMO TAT 2026 Abstract Book, a supplement to the official ESMO journal, ESMO Open.
Publication schedule for accepted abstracts
Details regarding the publication of accepted abstracts will be available in the “Press & Media” section in due course.
ESMO Merit Travel Grants
A restricted number of Merit Travel Grants to the ESMO Targeted Anticancer Therapies Congress 2026 are available, upon application, to first author (= presenter) who submit abstracts considered to be deserving of recognition. Candidates must be ESMO Members under the age of 40. Selection will be made by the ESMO TAT 2026 Scientific Committee on a competitive basis from among the accepted abstracts.
◆ 参会对象：医生、医院科室主任/副主任、住院医师、医院管理者、医护人员以及从事该领域研究的科学家、研究人员、医药企业代表等等。
|
